Arcturus Therapeutics (NASDAQ:ARCT) Share Price Crosses Below 200 Day Moving Average – What’s Next?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $12.22 and traded as low as $7.00. Arcturus Therapeutics shares last traded at $7.02, with a volume of 484,139 shares trading hands.

Analyst Ratings Changes

Several research analysts have weighed in on the company. HC Wainwright lowered their price objective on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Zacks Research cut Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Guggenheim downgraded shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday, January 21st. Finally, Citigroup dropped their price objective on shares of Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 6th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

Arcturus Therapeutics Stock Performance

The business’s 50 day moving average is $6.98 and its two-hundred day moving average is $12.17. The firm has a market capitalization of $215.06 million, a PE ratio of -3.08 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.60. The business had revenue of $17.15 million during the quarter, compared to analyst estimates of $17.47 million. Arcturus Therapeutics had a negative return on equity of 28.68% and a negative net margin of 68.35%. As a group, equities research analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ARCT. Sumitomo Mitsui Trust Group Inc. grew its position in Arcturus Therapeutics by 4.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,026,588 shares of the biotechnology company’s stock worth $12,423,000 after acquiring an additional 78,753 shares in the last quarter. Amova Asset Management Americas Inc. grew its holdings in shares of Arcturus Therapeutics by 6.4% in the third quarter. Amova Asset Management Americas Inc. now owns 1,947,835 shares of the biotechnology company’s stock worth $35,879,000 after purchasing an additional 117,632 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Arcturus Therapeutics by 4.2% in the third quarter. Vanguard Group Inc. now owns 1,885,605 shares of the biotechnology company’s stock valued at $34,752,000 after acquiring an additional 75,440 shares during the period. ARK Investment Management LLC increased its holdings in Arcturus Therapeutics by 9.2% during the 3rd quarter. ARK Investment Management LLC now owns 1,872,721 shares of the biotechnology company’s stock valued at $34,514,000 after purchasing an additional 157,681 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Arcturus Therapeutics by 112.0% during the third quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after buying an additional 327,626 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.